📊 FENC Key Takeaways
Is Fennec Pharmaceuticals Inc.. (FENC) a Good Investment?
Fennec Pharmaceuticals demonstrates deteriorating financial health with persistent operating losses, negative free cash flow, and critical balance sheet insolvency (negative stockholders' equity of -$4.5M). While strong gross margins (64.8%) and solid liquidity ratios indicate a viable business model, the company is burning cash faster than it can generate revenue, creating an unsustainable trajectory without significant operational turnaround or capital injection.
Fennec Pharmaceuticals shows a commercially viable product profile with solid gross margins and meaningful revenue, but the business is still not self-funding at the operating or free cash flow level. The combination of negative net income, negative free cash flow, weak interest coverage, and negative stockholders' equity materially weakens the balance sheet and raises the importance of execution improvement.
Why Buy Fennec Pharmaceuticals Inc.. Stock? FENC Key Strengths
- Strong gross margin of 64.8% indicates pricing power and efficient production in pharmaceutical sales
- Excellent liquidity position with current ratio of 4.69x and $21.9M cash buffer provides near-term runway
- Modest revenue base of $30.9M suggests potential for scaling if profitability improves
- Healthy gross margin of 64.8% indicates favorable product economics
- Strong current and quick ratios suggest near-term liquidity is adequate
- Revenue base of $30.86M shows the company has moved beyond a purely pre-revenue stage
FENC Stock Risks: Fennec Pharmaceuticals Inc.. Investment Risks
- Negative stockholders' equity of -$4.5M represents technical insolvency and balance sheet distress
- Negative free cash flow of -$8.0M (25.8% FCF margin) indicates unsustainable cash burn requiring capital financing
- Operating losses of -$3.7M on $30.9M revenue with negative operating margin of -12.1% show inability to cover core operations
- Negative interest coverage ratio of -2.1x indicates insufficient operating income to service debt obligations
- Net losses continuing with -$5.0M net income despite improving EPS metrics suggests operational challenges
- Negative stockholders' equity means liabilities exceed assets and limits balance sheet flexibility
- Operating cash flow of -$6.51M and free cash flow of -$7.95M indicate the business is still consuming cash
- Negative operating margin and interest coverage of -2.1x suggest debt servicing and profitability remain pressured
Key Metrics to Watch
- Path to operating profitability and timeline to positive EBITDA
- Monthly cash burn rate relative to $21.9M cash reserves and runway until capital necessity
- Revenue growth trajectory and whether top-line growth can offset fixed cost base
- Resolution of balance sheet insolvency through debt restructuring, capital raise, or operational improvement
- Operating cash flow and free cash flow trend toward breakeven
- Operating margin improvement and balance sheet recovery from negative equity
Fennec Pharmaceuticals Inc.. (FENC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.69x current ratio provides a solid financial cushion.
FENC Profit Margin, ROE & Profitability Analysis
FENC vs Healthcare Sector: How Fennec Pharmaceuticals Inc.. Compares
How Fennec Pharmaceuticals Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Fennec Pharmaceuticals Inc.. Stock Overvalued? FENC Valuation Analysis 2026
Based on fundamental analysis, Fennec Pharmaceuticals Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Fennec Pharmaceuticals Inc.. Balance Sheet: FENC Debt, Cash & Liquidity
FENC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Fennec Pharmaceuticals Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.02 indicates the company is currently unprofitable.
FENC Revenue Growth, EPS Growth & YoY Performance
FENC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $7.0M | -$638.0K | $-0.02 |
| Q2 2025 | $7.3M | -$1.2M | $-0.11 |
| Q1 2025 | $8.8M | -$1.2M | $-0.04 |
| Q3 2024 | $6.5M | $1.5M | $0.06 |
| Q2 2024 | $3.3M | -$5.4M | $-0.20 |
| Q1 2024 | $1.7M | -$6.1M | $-0.23 |
| Q3 2023 | $6.5M | -$1.9M | $-0.07 |
| Q2 2022 | $200.0K | -$3.7M | $-0.15 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Fennec Pharmaceuticals Inc.. Dividends, Buybacks & Capital Allocation
FENC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Fennec Pharmaceuticals Inc.. (CIK: 0001211583)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 7, 2026 | 8-K | fencf-20260407x8k.htm | View → |
| Apr 2, 2026 | 4 | xslF345X06/form4-04022026_040407.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/form4-04022026_040412.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/form4-04022026_040403.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/form4-04022026_040411.xml | View → |
❓ Frequently Asked Questions about FENC
What is the AI rating for FENC?
Fennec Pharmaceuticals Inc.. (FENC) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 79% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are FENC's key strengths?
Claude: Strong gross margin of 64.8% indicates pricing power and efficient production in pharmaceutical sales. Excellent liquidity position with current ratio of 4.69x and $21.9M cash buffer provides near-term runway. ChatGPT: Healthy gross margin of 64.8% indicates favorable product economics. Strong current and quick ratios suggest near-term liquidity is adequate.
What are the risks of investing in FENC?
Claude: Negative stockholders' equity of -$4.5M represents technical insolvency and balance sheet distress. Negative free cash flow of -$8.0M (25.8% FCF margin) indicates unsustainable cash burn requiring capital financing. ChatGPT: Negative stockholders' equity means liabilities exceed assets and limits balance sheet flexibility. Operating cash flow of -$6.51M and free cash flow of -$7.95M indicate the business is still consuming cash.
What is FENC's revenue and growth?
Fennec Pharmaceuticals Inc.. reported revenue of $30.9M.
Does FENC pay dividends?
Fennec Pharmaceuticals Inc.. pays dividends, with $0.2M distributed to shareholders in the trailing twelve months.
Where can I find FENC SEC filings?
Official SEC filings for Fennec Pharmaceuticals Inc.. (CIK: 0001211583) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is FENC's EPS?
Fennec Pharmaceuticals Inc.. has a diluted EPS of $-0.18.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is FENC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Fennec Pharmaceuticals Inc.. has a SELL rating with 79% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is FENC stock overvalued or undervalued?
Valuation metrics for FENC: ROE of N/A (sector avg: 15%), net margin of -16.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy FENC stock in 2026?
Our dual AI analysis gives Fennec Pharmaceuticals Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is FENC's free cash flow?
Fennec Pharmaceuticals Inc..'s operating cash flow is $-6.5M, with capital expenditures of $1.4M. FCF margin is -25.8%.
How does FENC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -16.1% (avg: 12%), ROE N/A (avg: 15%), current ratio 4.69 (avg: 2).